Keywords
primary health care
Prolanis
type 2 diabetes
hypertension
How to Cite
Abstract
Potential drug–drug interactions (pDDIs) are important factors resulting in adverse drug reactions or therapeutic failure. Therefore, pDDIs need to be identified to prevent the related risk and improve drug safety. The objective of this study was to assess the prevalence of pDDIs among Prolanis type 2 diabetes patients with hypertension. Additionally, this study aims to categorize and rate the identified pDDIs according to mechanism, severity and level of significance. This cross-sectional study was conducted at Kramat Jati District primary health care. Patient medical records from January to June 2018, were analysed using Drug Interaction Facts and Stockley’s Drug Interaction for pDDIs with a total 138 patients identified. pDDIs were detected in 35 patients (25.4%), with a total 57 interactions. They were clinically relevant with major (42.1%) in severity and refer to level one of significance (42.1%). The interaction type was unknown (64.9%), pharmacodynamic (64.9%) and pharmacokinetic (12.2%) respectively. The most common interaction was amlodipine-simvastatin in 19 cases (33.3%). Prolanis type 2 diabetes patients with hypertension were at risk to pDDIs, particularly to major pDDIs. Screening of prescriptions and medical records for pDDIs also monitoring of pharmacotherapy in terms of response and associated adverse drug events will contribute to patient safety.
References
Alvim MM, Silva LA, Leite IC, Silve´rio MS., 2015. Adverse events caused by potential drug-drug interactions in an intensive care unit of a teaching hospital. Rev Bras Ter Intensiva, 27, pp.353–359.
American Diabetes Association (ADA), 2017. Standards of Medical Care in Diabetes 2017. Diabetes Care, 40(Suppl.1), S1–S2.
American Heart Association (AHA)., 2016. Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients With Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation, 134, pp.e468–e495.
Badan Penelitian dan Pengembangan Kesehatan (Balitbangkes), 2018. Riset Kesehatan Dasar (Riskesdas) Tahun 2018. Jakarta: Kementerian Kesehatan.
Badan Penyelenggara Jaminan Sosial (BPJS), 2014. Panduan Praktis Prolanis (Program Pengelolaan Penyakit Kronis). [ONLINE] Available at: https://bpjs-kesehatan.go.id/bpjs/dmdocuments/06-PROLANIS.pdf.
Crea F, Liuzzo G, et al. Pathogenesis of Acute Coronary Syndromes. J Am Coll Cardiol. 2013 Jan, 61 (1) 1–11. https://doi.org/10.1016/j.jacc.2012.07.064
DeepthiEnumula, Muhammed Rashid, Sushmitha Sharma, GirishThunga, Shivashankar KN, Leelavathi D Acharya. 2021. Drug Related Problems in Type-2-Diabetes Mellitus with and Without Cardiovascular Diseases: A Systematic Review and Meta-Analysis. Annals of the Romanian Society for Cell Biology, 12623–12642. Retrieved from http://www.annalsofrscb.ro/index.php/journal/article/view/4196
Fahed G, Aoun L, Bou Zerdan M, Allam S, Bou Zerdan M, Bouferraa Y, Assi HI. Metabolic Syndrome: Updates on Pathophysiology and Management in 2021. International Journal of Molecular Sciences. 2022; 23(2):786. https://doi.org/10.3390/ijms23020786
Hartshorn EA, Tatro DS., 2012. Principles of Drug Interactions. In: Tatro DS (Eds.), Drug Interaction Facts: The Authority on Drug Interactions. California: Wolters Kluwel Health Inc.
Hidayah K, Kundarto W, Farida Y, 2018. Identifikasi Potensi Interaksi Obat pada Peresepan Obat Pasien Hipertensi dengan Diabetes Mellitus. Prosiding APC (Annual Pharmacy Conference), 3, pp.108-120.
Huri HZ, Wee HF., 2013. Drug related problems in type 2 diabetes patients with hypertension: a cross-sectional retrospective study. BMC Endocrine Disorders, 13, p.2.
International Diabetes Federation, 2022. IDF Diabetes Atlas, 9th edition. [ONLINE] Available at: https://diabetesatlas.org.
Ismail M, Noor S, Harram U, Haq I, Haider I, Khadim F, et al., 2018. Potential drug-drug interactions in the outpatient department of a tertiary care hospital in Pakistan: a cross-sectional study. BMC Health Services Research, 18, p.762.
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al., 2014. Evidence based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA, 311, pp.507-520.
Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, et al., 2013. 2013 ESH/ESC guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J, 34, pp.2159-2219.
Mukete, B. N., & Ferdinand, K. C., 2016. Polypharmacy in Older Adults With Hypertension: A Comprehensive Review. Journal of clinical hypertension (Greenwich, Conn.), 18(1), 10–18. https://doi.org/10.1111/jch.12624
Muti AF, Anindya C., 2021. Analysis of Potential Drug Interactions in Liver Cirrhosis Patients. Jurnal Farmasi Galenika: Galenika Journal of Pharmacy (e-Journal),7(1), pp.18-29.
Nurlaelah I, Mukaddas A, Faustine I., 2015. Kajian Interaksi Obat Pada Pengobatan Diabetes Melitus (Dm) Dengan Hipertensi Di Instalasi Rawat Jalan Rsud Undata Periode Maret-Juni Tahun 2014. GALENIKA Journal of Pharmacy, 1(1), pp.35-41.
Perreault, L., Skyler, J.S. & Rosenstock, J., 2021., Novel therapies with precision mechanisms for type 2 diabetes mellitus. Nat Rev Endocrinol 17, 364–377. https://doi.org/10.1038/s41574-021-00489-y
Perkumpulan Endokrinologi Indonesia (Perkeni), 2019. Pedoman Pengelolaan dan Pencegahan Diabetes Mellitus Tipe 2 Dewasa di Indonesia Tahun 2019. Jakarta: PB Perkeni.
Reusch JEB, Manson JE. Management of Type 2 Diabetes in 2017. Getting to Goal. JAMA. 2017;317(10):1015–1016. doi:10.1001/jama.2017.0241
Saibi Y, Hasan D, Shaqila V., 2018. Potensi Interaksi Obat pada Pasien Diabetes Melitus Tipe 2 di Rumah Sakit X Tangerang Selatan. JMPF, 8(3), pp.100-104.
Thürmann, Petra A.. 2020. Pharmacodynamics and pharmacokinetics in older adults. Current Opinion in Anaesthesiology 33(1):p 109-113,| DOI: 10.1097/ACO.0000000000000814
van den Anker, J., Reed, M.D., Allegaert, K. and Kearns, G.L. (2018), Developmental Changes in Pharmacokinetics and Pharmacodynamics. The Journal of Clinical Pharmacology, 58: S10-S25. https://doi.org/10.1002/jcph.1284
Yulia Khodneva, Anath Shalev, Stuart J. Frank, April P. Carson, Monika M. Safford, 2016, Calcium channel blocker use is associated with lower fasting serum glucose among adults with diabetes from the REGARDS study,
Diabetes Research and Clinical Practice,
Volume 115, Pages 115-121, ISSN 0168 8227, https://doi.org/10.1016/j.diabres.2016.01.021.(https://www.sciencedirect.com/science/article/pii/S016882271600070X)
Zazuli Z, Rohaya A, Adnyana IK., 2017. Drug-Related Problems in Type 2 Diabetic Patients with Hypertension: A Prospective Study. J Basic Clin Pharma, 8, pp.251-254.
All articles submitted by the author and published in the Journal of Research in Pharmacy and Pharmaceutical Sciences, are fully copyrighted by the publication of JJournal of Research in Pharmacy and Pharmaceutical Sciences under the Creative Commons Attribution-NonCommercial 4.0 International License by technically filling out the copyright transfer agreement and sending it to the publisher
Note :
The author can include in separate contractual arrangements for the non-exclusive distribution of rich versions of journal publications (for example: posting them to an institutional repository or publishing them in a book), with the acknowledgment of their initial publication in this journal.
Authors are permitted and encouraged to post their work online (for example: in an institutional repository or on their website) before and during the submission process because it can lead to productive exchanges, as well as earlier and more powerful citations of published works. (See Open Access Effects).